Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 1.00 |
| ▸ | CHUK | O15111 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | PLA2G2A | P14555 | 1/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL13026138 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL13046610 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL3392690 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL24556970 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL12738245 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL23022353 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL20816248 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21790369 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21261932 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL11911310 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| EP-1143950-B1 | TOPICAL APPLICATION PRODUCTS AGAINST ONYCHOMYCOSES | BIOEQUAL AG (CH) | 2005-03-09 | — | — | EP | claimed |
| EP-1448202-A1 | COMBINATION OF A PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA Pharma AG (DE) | 2004-08-25 | — | — | EP | claimed |
| WO-2003039552-A1 | COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA PHARMA AG (DE) | 2003-05-15 | — | — | WO | claimed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | claimed |
| US-4011317-A | STEROID DERIVATIVES | RORER ITALIANA S.P.A. (IT) | 1977-03-08 | — | — | US | claimed |
| EP-3838270-A2 | SYNERGISTIC PHARMACEUTICAL COMPOSITION COMPRISING ACECLOFENAC AND BETAMETHASONE FOR THE TREATMENT OF PAIN IN LOCALISED FORMS OF RHEUMATIC ILLNESSES | Amézcua Amézcua, Federico (MX) | 2021-06-23 | — | — | EP | disclosed |
| EP-3701941-A1 | CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN | Flexion Therapeutics, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-2600836-B1 | CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN | FLEXION THERAPEUTICS INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10624905-B2 | Corticosteroids for the treatment of joint pain | FLEXION THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180311260-A1 | CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN | PACIRA CRYOTECH, INC. | 2018-11-01 | — | — | US | disclosed |
| US-9949987-B2 | Corticosteroids for the treatment of joint pain | FLEXION THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170182068-A1 | CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN | PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.) | 2017-06-29 | — | — | US | disclosed |
| EP-0977725-B1 | NEW FATTY ACID DERIVATIVES | CONPHARMA AS (NO) | 2004-06-16 | — | — | EP | disclosed |
| US-6740326-B1 | WATER-FREE TOPICAL APPLICATION COMPOSITION FOR TREATMENT OF NAIL DISEASES AND NAIL CARE CONSISTING OF ANTIMYCOTIC AGENT AND LOWER ALKYL ESTER OF LACTIC ACID, MALIC ACID, TARTARIC ACID OR CITRIC ACID AS PENETRATION PROMOTING CARRIER | BIOEQUAL AG (CH) | 2004-05-25 | — | — | US | disclosed |
| US-20030153544-A1 | Lipophilic biologically active compound containing in its molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, acid and ester in which one group is replaced by lipophilic group | CONPHARMA AS (NO) | 2003-08-14 | — | — | US | disclosed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | disclosed |
| EP-0137212-A2 | Ointment bases and ointments | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-04-17 | — | — | EP | disclosed |
| EP-0095749-A2 | 17-Spiroandrostenes | E.R. Squibb & Sons, Inc. (US) | 1983-12-07 | — | — | EP | disclosed |
| US-4397782-A | Antiinflammatory 17-spiroandrostenes | E. R. SQUIBB & SONS, INC. (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182068-A1 | CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN | CRH, NR3C1, MC2R | NR3C1 2/4885HIF1A 3175/4885CYP3A4 977/4885 |
| US-20030153544-A1 | Lipophilic biologically active compound containing in its molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, acid and ester in which one group is replaced by lipophilic group | TSPO, NR1H2, NR1H3 | NR3C1 592/4885HIF1A 3950/4885CYP3A4 814/4885 |
| US-20180311260-A1 | CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN | CRH, NR3C1, MC2R | NR3C1 2/4885HIF1A 3175/4885CYP3A4 977/4885 |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | NR3C1 104/4885HIF1A 1076/4885CYP3A4 2529/4885 |
| US-10624905-B2 | Corticosteroids for the treatment of joint pain | CRH, NR3C1, MC2R | NR3C1 2/4885HIF1A 3175/4885CYP3A4 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.